Cette stratégie s’inscrit dans la continuité des Novartis Access Principles, qui visent à intégrer systématiquement des stratégies d’accès dans la manière dont l’entreprise recherche, développe et commercialise ses médicaments dans le monde entier
Une unité récemment formée pour l’Afrique subsaharienne déploiera des approches innovantes pour atteindre davantage de patients, sur l’ensemble de la pyramide des revenus
Novartis se base sur ses activités établies dans le domaine du paludisme, du cancer, de la drépanocytose et des maladies cardiovasculaires, ainsi que sur ses modèles d’entreprises sociales qui ont fait leurs preuves sur ce continent
L’Afrique supporte un quart du fardeau mondial des maladies, mais seuls 3% des professionnels de la santé dans le monde sont basés sur ce continent. Par ailleurs, moins de 1% des dépenses de santé mondiales sont réalisées en Afrique1.
Press Release
Cette stratégie s’inscrit dans la continuité des Novartis Access Principles, qui visent à intégrer systématiquement des stratégies d’accès dans la manière dont l’entreprise recherche, développe et commercialise ses médicaments dans le monde entier
Une unité récemment formée pour l’Afrique subsaharienne déploiera des approches innovantes pour atteindre davantage de patients, sur l’ensemble de la pyramide des revenus
Novartis se base sur ses activités établies dans le domaine du paludisme, du cancer, de la drépanocytose et des maladies cardiovasculaires, ainsi que sur ses modèles d’entreprises sociales qui ont fait leurs preuves sur ce continent
L’Afrique supporte un quart du fardeau mondial des maladies, mais seuls 3% des professionnels de la santé dans le monde sont basés sur ce continent. Par ailleurs, moins de 1% des dépenses de santé mondiales sont réalisées en Afrique1.
Government is already working to accelerate inclusion of the medicine and associated laboratory testing in the National Health Insurance Scheme
Novartis has already delivered more than 20 000 treatments1 and is committed to implementing two clinical trials with novel biologic treatment for sickle cell disease
Partnership includes establishing national treatment guidelines, newborn screening, and centers of excellence for treatment of sickle cell disease; making accessible treatment options available in line with the global standards of care; and using digital technologies to monitor and evaluate patient registration, report real-time data, and help ensure safe large scale roll-out of medicine
15 000 babies are born with sickle cell disease every year in Ghana2
Press Release
Government is already working to accelerate inclusion of the medicine and associated laboratory testing in the National Health Insurance Scheme
Novartis has already delivered more than 20 000 treatments1 and is committed to implementing two clinical trials with novel biologic treatment for sickle cell disease
Partnership includes establishing national treatment guidelines, newborn screening, and centers of excellence for treatment of sickle cell disease; making accessible treatment options available in line with the global standards of care; and using digital technologies to monitor and evaluate patient registration, report real-time data, and help ensure safe large scale roll-out of medicine
15 000 babies are born with sickle cell disease every year in Ghana2
The Novartis Foundation is sharpening its focus to concentrate fully on reimagining how data, digital and AI can transform global health.
Press Release
BASEL, Switzerland, July 8, 2019 /3BL Media/ – The Novartis Foundation is sharpening its focus to concentrate fully on reimagining how data, digital and AI can transform global health. This new mandate builds on 40 years of striving for sustainable impact on health in low-income populations, most recently by focusing on leprosy elimination and cardiovascular health, in addition to digital health.
The Working Group for Primary Healthcare Transformation should complement the government’s efforts to strengthen primary healthcare to achieve Universal Health Coverage (UHC) in Vietnam.
Press Release
HANOI, Vietnam, May 21, 2019 /3BL Media/– A new public-private partnership, comprising the Vietnamese Ministry of Health, and three other founding members, i.e. World Economic Forum (WEF), Harvard Medical School Center for Primary Care and Novartis could transform primary healthcare in Vietnam. As announced by the Vietnamese Ministry of Health, this innovative public-private partnership will help deliver on the Ministry of Health’s objectives the Vietnamese Ministry of Health by strengthening existing primary care demonstration projects in 30 provinces.
Asian experts surveyed in a new report fear that the last mile in malaria elimination in the region is threatened by increasing resistance to antimalarials and insecticides – new tools will be needed to defeat the disease.
Summary:
Asian experts fear that the last mile in malaria elimination in the region is threatened by increasing resistance to antimalarials and insecticides – new tools will be needed to defeat the disease
Another major hurdle to meeting elimination targets in South and Southeast Asia will be reaching mobile and migrant populations in remote areas
Elimination will also depend on countries in the region maintaining malaria expertise as they develop their primary healthcare services
Press Release
Asian experts fear that the last mile in malaria elimination in the region is threatened by increasing resistance to antimalarials and insecticides – new tools will be needed to defeat the disease
Another major hurdle to meeting elimination targets in South and Southeast Asia will be reaching mobile and migrant populations in remote areas
Elimination will also depend on countries in the region maintaining malaria expertise as they develop their primary healthcare services
The European & Developing Countries Clinical Trials Partnership (EDCTP) grants €10 million over five years to “WANECAM 2” a unique collaboration between antimalarial drug researchers in Africa and Europe from ten academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture.
The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation. KAF156 has demonstrated the potential to treat resistant malaria and to be administered as a single dose.
The grant will also help to build and strengthen research capabilities in the four participating African countries: Burkina Faso, Gabon, Mali and Niger.
Press Release
The European & Developing Countries Clinical Trials Partnership (EDCTP) grants €10 million over five years to “WANECAM 2” a unique collaboration between antimalarial drug researchers in Africa and Europe from ten academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture.
The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation. KAF156 has demonstrated the potential to treat resistant malaria and to be administered as a single dose.
The grant will also help to build and strengthen research capabilities in the four participating African countries: Burkina Faso, Gabon, Mali and Niger.
The Novartis Foundation and Microsoft are partnering to develop an Artificial Intelligence (AI)-enabled Digital Health tool and a Leprosy Intelligent Image Atlas to aid in the early detection of leprosy
Press Release
BASEL, Switzerland, March 26, 2018 /3BL Media/ – The Novartis Foundation and Microsoft are partnering to develop an Artificial Intelligence (AI)-enabled Digital Health tool and a Leprosy Intelligent Image Atlas to aid in the early detection of leprosy. Over 200,000 people are diagnosed with leprosy every year. Brazil, India, and Indonesia account for about 80% of new cases. If untreated, patients are left with lifelong disabilities and are often stigmatized in their societies.
Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5
Press Release
Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5
